Allergy Therapeutics (AGY): Potential equity raise
This situation live
AGY Allergy Therapeutics
12 Dec 2025 · Authority sought; no investors or terms agreed · +13% until the next step
At this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price o
19 Jan 2026 · No raise agreed; £70m uncommitted debt funding available · −11% until the next step
Together with the previously announced £20 million uncommitted Hayfin facility, the Group has access to total uncommitted funding of £70 million, while it continues to explore a potential dual primary
31 Mar 2026 · No raise; £40m Hayfin debt drawn · −43% until the next step
Following receipt of the 2026 Hayfin Facility proceeds, the Group has sufficient funds for the entirety of the twelve-month going concern review period, while it continues to explore a listing in Hong
29 Jul 2026 · No raise; debt funded, cash £24.2m · −24% since
In addition, the Shareholder Lenders agreed to provide a new £50 million unsecured loan facility although no amounts had been drawn as at 30 June 2026.
Potential equity raise
No raise; debt funded, cash £24.2m
Next: preliminary audited results
Every step · 4
- 12 Dec 2025 Authority sought; no investors or terms agreed – At this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to... ↗
- 19 Jan 2026 No raise agreed; £70m uncommitted debt funding available – Together with the previously announced £20 million uncommitted Hayfin facility, the Group has access to total uncommitted funding of £70 million, while it... ↗
- 31 Mar 2026 No raise; £40m Hayfin debt drawn – Following receipt of the 2026 Hayfin Facility proceeds, the Group has sufficient funds for the entirety of the twelve-month going concern review period,... ↗
- 29 Jul 2026 No raise; debt funded, cash £24.2m – In addition, the Shareholder Lenders agreed to provide a new £50 million unsecured loan facility although no amounts had been drawn as at 30 June 2026. ↗
What is happening
Allergy Therapeutics: Potential equity raise – No raise; debt funded, cash £24.2m. ['No raise; debt funded, cash £24.2m']
- In short
- In December 2025 the Board sought authority to issue up to 610m shares without pre-emption, but no raise was agreed. Shareholder loans were repaid via £55m warrant exercises and a £40m Hayfin facility was drawn. At 30 June 2026 cash was £24.2m, with a new £50m unsecured shareholder facility undrawn.
- Announced
- 12 Dec 2025 · Authority sought; no investors or terms agreed
- Latest
- 29 Jul 2026 · No raise; debt funded, cash £24.2m
- New facility
- £40m senior secured 2026 Hayfin Facility, drawn immediately after period end
- Cash
- £24.2m at 30 June 2026 (30 June 2025: £12.8m), unaudited
- Debt
- £20.2m at 31 December 2025 (30 June 2025: £53.4m)
- Warrant exercise
- £55m shareholder lender warrants exercised; shareholder loan repaid in full
- Hayfin facility
- £40m senior secured, immediately drawn down
- Warrant proceeds
- £55m, applied to repay all shareholder lender debt
- Undrawn facility
- £50m unsecured shareholder loan, nothing drawn at 30 June 2026
- Next milestone
- Preliminary audited results in October 2026
What comes next
preliminary audited results.
Briefing Pro
New to Allergy Therapeutics? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the AGY briefing →From the company's own announcements. Not investment advice.
Also at Allergy Therapeutics 1 open
Project milestonesVLP Peanut PROTECT trial – Still exploring; no timetable
Allergy Therapeutics – company page →